TLR7 and neoplasm: To determine if evidence immune activation following TransCon TLR7/8 Agonist treatment was detectable in peripheral circulation, we administered TransCon TLR7/8 Agonist (40, 80, or 200 μg resiquimod equivalent) IT in CT26 tumor bearing mice and levels of peripheral proinflammatory cytokines/chemokines and phenotypes of immune cells were evaluated.